Tradestie Institutional Equity Comparison Engine

KYMR vs CRSP โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

KYMR Overall Edge

KYMR Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Kymera Therapeutics, Inc. Common Stock (KYMR) driven by superior Momentum & Technical, Options & Structure while CRSP counters with relative strength in Valuation, Growth & Margin. Fundamentally, KYMR trades at N/M Forward P/E with -396.0% operating margin (+466.4% YoY revenue) versus CRSP at 23.4x Forward P/E and -2058.6% operating margin (+1325.1% YoY). In options structure, KYMR sits in CONSOLIDATION (23rd %ile IV; Dealer Gamma Walls on Pro) against CRSP sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CRSP
KYMR N/M vs CRSP 23.4x Fwd P/E
Growth & Margin Winner CRSP
Op Margin -396.0% vs -2058.6% ยท YoY +466.4% vs +1325.1%
Momentum & Technical Winner KYMR
1Y +96.1% vs -20.5% ยท 52W Pos 78% vs 1%
Options & Structure Winner KYMR
CONSOLIDATION (23rd %ile IV) vs BREAKDOWN (52nd %ile IV)
KYMR NASDAQ
Kymera Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$124.79
-2.18% 1D
Market Cap $10.9B
1M Return +19.1%
1Y Return +96.12%
Forward P/E N/M
Unified AI Score
47.1 / 100 HOLD
Tech 36.0 Fund 50.0 Flow 67.0 Mom 50.0
CRSP NASDAQ
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
1M Return -17.54%
1Y Return -20.54%
Forward P/E 23.4x
Unified AI Score
44.7 / 100 HOLD
Tech 25.0 Fund 52.0 Flow 68.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: KYMR +96.12% CRSP -20.54% Spread: +116.66 pp (KYMR Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period KYMR Revenue CRSP Revenue KYMR Op. Margin CRSP Op. Margin Margin Edge
FY2018 N/A $0M N/A -5087.8% CRSP
FY2019 $0M $290M -1438.5% 16.1% CRSP
FY2020 $30M $0M -136.1% -49295.5% KYMR
FY2021 $70M $910M -138.0% 40.8% CRSP
FY2022 $50M $0M -344.4% -56190.4% KYMR
FY2023 $80M $370M -210.6% -60.0% CRSP
FY2024 $50M $40M -555.8% -1250.4% KYMR
FY2025 $40M $0M -891.1% -18933.6% KYMR

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: KYMR (5) vs CRSP (4)
Institutional Metric KYMR CRSP Criterion Row Winner
Market Capitalization Scale $10.9B $4.1B Larger Scale KYMR
Trailing P/E Ratio Valuation N/M 23.4x Lower Multiple CRSP
Forward P/E Ratio Valuation N/M 23.4x Lower Multiple CRSP
Revenue Growth (YoY) Growth +466.4% +1325.1% Higher Growth CRSP
Operating Margin (TTM) Profitability -396.0% -2058.6% Higher Margin KYMR
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -27.3% -25.6% Higher ROE CRSP
52-Week Range Position Momentum 78% ($62โ€“$143) 1% ($40โ€“$63) Stronger Trend KYMR
Beta / 30D Volatility Risk Regime 1.04ฮฒ ยท 54% Vol 1.85ฮฒ ยท 60% Vol Lower Realized Risk KYMR
Unified Institutional Score Composite Signal 47.1 / 100 (HOLD) 44.7 / 100 (HOLD) Higher Composite KYMR

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full KYMR vs CRSP Buy Guide
KYMR CONSOLIDATION
62d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 23rd %ile
IV Regime Compressed (<25th %ile)
Live KYMR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CRSP BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CRSP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither KYMR nor CRSP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.